SAREUM HOLDINGS PLC

Regulatory Filings • Dec 18, 2024

National Storage Mechanism | Additional information

RNS Number : 4779Q

Sareum Holdings PLC

18 December 2024

Sareum Holdings plc

("Sareum" or the "Company")

Appointment of Joint Broker

Cambridge, UK, 18 December 2024 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, is pleased to announce the appointment of  Oberon Capital   as a Joint Corporate Broker with immediate effect.  Oberon Capital is a trading name of Oberon Investments Limited.

Strand  Hanson Limited   and  Hybridan LLP   will continue to act as the Company's Nominated Adviser and Joint Corporate Broker, respectively.

- Ends -

For further information, please contact: 

Sareum Holdings plc Stephen Parker, Executive Chairman	01223 497700 ir@sareum.co.uk
Strand Hanson Limited (Nominated Adviser) James Dance / James Bellman	020 7409 3494
Oberon Capital (J oint Broker) Mike Seabrook / Nick Lovering Hybridan LLP (J oint Broker) Claire Noyce	020 3179 5300 020 3764 2341
ICR Healthcare (Financial PR) Jessica Hodgson / Davide Salvi / K umail Waljee	0203 709 5700

About Sareum

Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases and has completed Phase 1 clinical development and is readying for phase 2 trials.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.

Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

APPFZMMZNNDGDZM